LAS VEGAS, Jan. 5, 2018 /PRNewswire/ -- Digipath, Inc. (OTCQB: DIGP) ("DIGP" or the "Company"), a service oriented independent testing laboratory and media firm focused on the developing cannabis market, today announced that Digipath Labs, its wholly owned subsidiary, has been awarded Emerald Test Badges for Potency and Pesticides Testing. Emerald Test recognition demonstrates the lab's proficiency and commitment to a higher standard of excellence in Cannabis Testing. The Emerald Test Badge results provide a measure of assurance and reliability to the industry as a whole, and particularly to those who depend on testing lab's results for safety, health, and product performance.
In anticipation of ISO 17025 accreditation, Digipath Labs participated in three Emerald Cup tests (pesticides, potency and terpenes) during the Fall 2017 competition. The Emerald Test® uses the standard Inter-laboratory Comparison Proficiency Testing (ILC/PT) program for evaluating how accurately and dependably testing labs perform, by comparing how well the lab measures blinded samples. ILC/PT programs are common in many testing industries, including environmental, food, pharmaceutical, water and petrochemical, providing a point of reference on how well the testing labs are performing individually and as a group. Individual labs can use their ILC/PT results to either verify proficiency to their customers and state regulatory bodies or to point out analytical tests needing further validation effort. This Fall also marked the first time that terpenoids were included as a separate test and because of that, no badges were awarded.
Todd Denkin, Digipath's President & COO, commented, "We are quite proud to win these awards as they validate Dr. Orser's and Digipath Lab's mandate to be the industry leader in cannabis lab testing, science and analytics."
The Pesticides Test is comprised of 22 analytes in hemp matrix, with quantities ranging from 0-1000 ng/g. A blank matrix sample is also provided. The Emerald Potency Test requires the quantitative determination of five cannabinoids: THC, THC-A, CBD, CBDA and CBN in acetonitrile between 0 to 1,000 µg/ml. In previous, single-analyte tests, the Emerald badge was awarded to labs, which performed at or below +/-10% of the actual value of the test. However, with multiple-analyte tests, the calculations become more difficult. The Advisory Panel has recommended the use of a Z score of +/-1 to qualify for the badge. This is a more robust and rational statistical evaluation that will be performed after all of the test data has been received.
About Digipath, Inc. (OTCQB: DIGP)
Digipath, Inc., supports the cannabis industry's best practices for reliable cannabis testing and education and brings unbiased cannabis news coverage to the cannabis industry.
Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client's products through analysis, research, development, and standardization.
Information about Forward-Looking Statements
This press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company's need for additional funding, the demand for the Company's products, governmental regulation of the cannabis industry, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Viridian Capital Advisors, LLC
SOURCE DigiPath, Inc.